Page 62 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 7 of 10 Review Article

Data availability statement 20. Wandeler G, Keiser O, Mulenga L, et al. Tenofovir in second-line ART in Zambia
and South Africa: Collaborative analysis of cohort studies. J Acquir Immune Defic
Syndr. 2012;61(1):41–48. https://doi.org/10.1097/QAI.0b013e3182632540
Data sharing is not applicable to this article as no new data 21. Mberi MN, Kuonza LR, Dube NM, Nattey C, Manda S, Summers R. Determinants of
were created or analysed in this study. loss to follow-up in patients on antiretroviral treatment, South Africa, 2004-2012:
A cohort study. BMC Health Serv Res. 2015;15:259. https://doi.org/10.1186/
s12913-015-0912-2
Disclaimer 22. Fatti G, Mothibi E, Meintjes G, Grimwood A. Antiretroviral treatment outcomes
amongst older adults in a large multicentre cohort in South Africa. PLoS One.
2014;9(6):e100273. https://doi.org/10.1371/journal.pone.0100273
The views expressed in this article are the authors’ own and 23. Brennan AT, Maskew M, Ive P, et al. Increases in regimen durability associated
not an official position of any of our institutions or funders. with the introduction of tenofovir at a large public-sector clinic in Johannesburg,
South Africa. J Int AIDS Soc. 2013;16. https://doi.org/10.7448/IAS.16.1.18794
References 24. Brennan AT, Shearer K, Maskew M, Long L, Sanne I, Fox MP. Impact of choice of
NRTI in first-line antiretroviral therapy: A cohort analysis of stavudine vs. tenofovir.
Trop Med Int Health. 2014;19(5):490–498. https://doi.org/10.1111/tmi.12285
1. UNAIDS. South Africa Overview: UNAIDS [homepage on the Internet]. 2018 25. Evans D, Maskew M, Sanne I. Increased risk of mortality and loss to follow-up
[cited 2018 Apr 13]. Available from: http://www.unaids.org/en/regionscountries/ among HIV-positive patients with oropharyngeal candidiasis and malnutrition
countries/southafrica. before antiretroviral therapy initiation: A retrospective analysis from a large urban
cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol.
2. Rosen S FM. Retention on antiretroviral therapy in South Africa: Evidence from a 2012;113(3):362–372. https://doi.org/10.1016/j.oooo.2011.09.004
systematic review. Johannesburg: Health Economics and Epidemiology Research
Office; 2014, Number 8. 26. Evans D, Takuva S, Rassool M, Firnhaber C, Maskew M. Prevalence of peripheral
neuropathy in antiretroviral therapy naive HIV-positive patients and the impact
3. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent on treatment outcomes – A retrospective study from a large urban cohort in
antiretroviral therapy programmes in lower-income countries. Bull World Health Johannesburg, South Africa. J Neurovirol. 2012;18(3):162–171. https://doi.org/
Organ. 2008;86(7):559–567. https://doi.org/10.2471/BLT.07.044248 10.1007/s13365-012-0093-2
4. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes 27. Fox MP, Shearer K, Maskew M, et al. Treatment outcomes after 7 years of public-
among adult patients initiating antiretroviral therapy across South Africa, sector HIV treatment. AIDS. 2012;26(14):1823–1828. https://doi.org/10.1097/
2002–2007. AIDS. 2010;24(14):2263–2270. https://doi.org/10.1097/QAD.0b013e QAD.0b013e328357058a
32833d45c5 28. Fox MP, Maskew M, MacPhail AP, et al. Cohort profile: The Themba Lethu clinical
5. Grimsrud A, Balkan S, Casas EC, et al. Outcomes of antiretroviral therapy over a cohort, Johannesburg, South Africa. Int J Epidemiol. 2013;42(2):430–439. https://
10-year period of expansion: A multicohort analysis of African and Asian HIV doi.org/10.1093/ije/dys029
programs. J Acquir Immune Defic Syndr. 2014;67(2):E55–E66. https://doi.org/
10.1097/QAI.0000000000000268 29. Fox MP, Shearer K, Maskew M, Meyer-Rath G, Clouse K, Sanne I. Attrition through
multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One.
6. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 2014;9(10):e110252. https://doi.org/10.1371/journal.pone.0110252
7 years of scale-up at a community-based antiretroviral treatment service in
South Africa. J Acquir Immune Defic Syndr. 2011;56(1):e1–e8. https://doi.org/ 30. Maskew M, Brennan AT, MacPhail AP, Sanne IM, Fox MP. Poorer ART outcomes
10.1097/QAI.0b013e3181ff0bdc with increasing age at a large public sector HIV clinic in Johannesburg, South Africa.
J Int Assoc Physicians AIDS Care (Chic). 2012;11(1):57–65. https://doi.org/
7. Bock P, Fatti G, Ford N, et al. Attrition when providing antiretroviral treatment at 10.1177/1545109711421641
CD4 counts >500cells/muL at three government clinics included in the HPTN 071
(PopART) trial in South Africa. PLoS One. 2018;13(4):e0195127. https://doi. 31. Shearer K, Fox MP, Maskew M, Berhanu R, Long L, Sanne I. The impact of choice of
org/10.1371/journal.pone.0195127 NNRTI on short-term treatment outcomes among HIV-infected patients prescribed
tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013;8(8):
8. Grimsrud A, Cornell M, Schomaker M, et al. CD4 count at antiretroviral therapy e71719. https://doi.org/10.1371/journal.pone.0071719
initiation and the risk of loss to follow-up: Results from a multicentre cohort study.
J Epidemiol Commun Health. 2016;70(6):549–555. https://doi.org/10.1136/jech- 32. Westreich D, Evans D, Firnhaber C, Majuba P, Maskew M. Prevalent pregnancy,
2015-206629 biological sex, and virologic response to antiretroviral therapy. J Acquir Immun
Defic Syndr. 2012;60(5):489–494. https://doi.org/10.1097/QAI.0b013e318256b310
9. Lilian RR, Mutasa B, Railton J, et al. A 10-year cohort analysis of routine paediatric 33. Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM. Effectiveness and safety of
ART data in a rural South African setting. Epidemiol Infect. 2017;145(1):170–180. 30 mg versus 40 mg stavudine regimens: A cohort study among HIV-infected
https://doi.org/10.1017/S0950268816001916 adults initiating HAART in South Africa. J Int AIDS Soc. 2012;15(1):13. https://doi.
10. Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up org/10.1186/1758-2652-15-13
in HIV treatment programs: A statistical analysis of 111 facilities in Africa, Asia, 34. Clouse K, Pettifor AE, Maskew M, et al. Patient retention from HIV diagnosis
and Latin America. PLoS Med. 2011;8(10):e1001111. https://doi.org/10.1371/ through one year on antiretroviral therapy at a primary health care clinic in
journal.pmed.1001111 Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013;62(2):e39–e46.
11. Grimsrud AT, Cornell M, Egger M, Boulle A, Myer L. Impact of definitions of loss to https://doi.org/10.1097/QAI.0b013e318273ac48
follow-up (LTFU) in antiretroviral therapy program evaluation: Variation in the 35. Lessells RJ, Mutevedzi PC, Iwuji CC, Newell ML. Reduction in early mortality on
definition can have an appreciable impact on estimated proportions of LTFU. J Clin antiretroviral therapy for adults in rural South Africa since change in CD4+ cell
Epidemiol. 2013;66(9):1006–1013. https://doi.org/10.1016/j.jclinepi.2013.03.013 count eligibility criteria. J Acquir Immune Defic Syndr. 2014;65(1):e17–e24.
12. Johnson LF, Estill J, Keiser O, et al. Do increasing rates of loss to follow-up in https://doi.org/10.1097/QAI.0b013e31829ceb14
antiretroviral treatment programs imply deteriorating patient retention? Am 36. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell M-L. Association of age with
J Epidemiol. 2014;180(12):1208–1212. https://doi.org/10.1093/aje/kwu295 mortality and virological and immunological response to antiretroviral therapy in
13. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for rural South African adults. PLoS One. 2011;6(7):e21795. https://doi.org/10.1371/
systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. journal.pone.0021795
2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097 37. Fatti G, Grimwood A, Mothibi E, Shea J. The effect of patient load on antiretroviral
14. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing treatment programmatic outcomes at primary health care facilities in South Africa:
the quality of nonrandomised studies in meta-analyses [homepage on the A multicohort study. J Acquir Immune Defic Syndr. 2011;58(1):e17–e19. https://
Internet]. Ottawa Hospital Research Institute; 2014 [updated 2014; cited 2017 doi.org/10.1097/QAI.0b013e318229baab
Jan 14]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/ 38. Grimsrud A, Sharp J, Kalombo C, Bekker L-G, Myer L. Implementation of
oxford.asp community-based adherence clubs for stable antiretroviral therapy patients in
15. Shearer K, Brennan AT, Maskew M, et al. The relation between efavirenz versus Cape Town, South Africa. J Int AIDS Soc. 2015;18:19984. https://doi.org/10.7448/
nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. IAS.18.1.19984
2014;17:19065. https://doi.org/10.7448/IAS.17.1.19065 39. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident
16. Clouse K, Pettifor A, Maskew M, et al. Initiating antiretroviral therapy when tuberculosis are independent risk factors for mortality among patients accessing
presenting with higher CD4 cell counts results in reduced loss to follow-up in a antiretroviral therapy in South Africa. PLoS One. 2013;8(2):e55824. https://doi.
resource-limited setting. AIDS. 2013;27(4):645–650. https://doi.org/10.1097/ org/10.1371/journal.pone.0055824
QAD.0b013e32835c12f9 40. Nglazi MD, Kranzer K, Holele P, et al. Treatment outcomes in HIV-infected adolescents
17. Evangeli M, Newell ML, Richter L, McGrath N. The association between self- attending a community-based antiretroviral therapy clinic in South Africa.
reported stigma and loss-to-follow up in treatment eligible HIV positive adults in BMC Infec Dis. 2012;12(21). https://doi.org/10.1186/1471-2334-12-21
rural Kwazulu-Natal, South Africa. PLoS One. 2014;9(2):e88235. https://doi.org/ 41. Orrell C, Kaplan R, Wood R, Bekker L-G. Virological breakthrough: A risk factor for
10.1371/journal.pone.0088235 loss to followup in a large community-based cohort on antiretroviral therapy. AIDS
18. Evans D, Menezes C, Mahomed K, et al. Treatment outcomes of HIV-infected Res Treat. 2011;469127. https://doi.org/10.1155/2011/469127
adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, 42. Davies N, Karstaedt AS. Antiretroviral outcomes in South African prisoners:
South Africa. AIDS Res Hum Retrovir. 2013;29(6):892–900. https://doi.org/10.1089/ A retrospective cohort analysis. PLoS One. 2012;7(3):e33309. https://doi.org/
aid.2012.0215 10.1371/journal.pone.0033309
19. Cornell M, Johnson LF, Schomaker M, et al. Age in antiretroviral therapy 43. Boulle A, Schomaker M, May MT, et al. Mortality in patients with HIV-1 infection
programmes in South Africa: A retrospective, multicentre, observational cohort starting antiretroviral therapy in South Africa, Europe, or North America:
study. Lancet HIV. 2015;2(9):e368–e375. https://doi.org/10.1016/S2352-3018(15) A collaborative analysis of prospective studies. PLoS Med. 2014;11(9):e1001718.
00113-7 https://doi.org/10.1371/journal.pmed.1001718
http://www.sajhivmed.org.za 55 Open Access